カルナバイオサイエンスの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2018/12/11 | 1,182 | 1,186 | 1,144 | 1,144 | -21 | -1.8% | 93,200 |
| 2018/12/10 | 1,213 | 1,232 | 1,149 | 1,165 | -86 | -6.9% | 188,300 |
| 2018/12/07 | 1,276 | 1,291 | 1,235 | 1,251 | -25 | -2% | 73,000 |
| 2018/12/06 | 1,342 | 1,349 | 1,268 | 1,276 | -79 | -5.8% | 138,400 |
| 2018/12/05 | 1,313 | 1,362 | 1,303 | 1,355 | +13 | +1% | 84,500 |
| 2018/12/04 | 1,370 | 1,385 | 1,338 | 1,342 | -27 | -2% | 122,800 |
| 2018/12/03 | 1,372 | 1,388 | 1,357 | 1,369 | -3 | -0.2% | 107,200 |
| 2018/11/30 | 1,348 | 1,373 | 1,335 | 1,372 | +10 | +0.7% | 98,500 |
| 2018/11/29 | 1,345 | 1,373 | 1,334 | 1,362 | +25 | +1.9% | 121,700 |
| 2018/11/28 | 1,290 | 1,339 | 1,286 | 1,337 | +52 | +4% | 148,700 |
| 2018/11/27 | 1,250 | 1,290 | 1,239 | 1,285 | +52 | +4.2% | 110,100 |
| 2018/11/26 | 1,231 | 1,243 | 1,213 | 1,233 | -3 | -0.2% | 55,800 |
| 2018/11/22 | 1,205 | 1,236 | 1,197 | 1,236 | +31 | +2.6% | 49,600 |
| 2018/11/21 | 1,190 | 1,223 | 1,181 | 1,205 | ±0 | ±0% | 55,200 |
| 2018/11/20 | 1,213 | 1,223 | 1,193 | 1,205 | -33 | -2.7% | 72,600 |
| 2018/11/19 | 1,208 | 1,248 | 1,198 | 1,238 | +30 | +2.5% | 80,900 |
| 2018/11/16 | 1,213 | 1,230 | 1,191 | 1,208 | -5 | -0.4% | 63,400 |
| 2018/11/15 | 1,210 | 1,227 | 1,175 | 1,213 | +19 | +1.6% | 135,700 |
| 2018/11/14 | 1,216 | 1,230 | 1,176 | 1,194 | -22 | -1.8% | 121,600 |
| 2018/11/13 | 1,162 | 1,232 | 1,162 | 1,216 | +1 | +0.1% | 124,000 |
| 2018/11/12 | 1,326 | 1,326 | 1,206 | 1,215 | -130 | -9.7% | 346,800 |
| 2018/11/09 | 1,425 | 1,500 | 1,315 | 1,345 | -27 | -2% | 1,113,800 |
| 2018/11/08 | 1,325 | 1,372 | 1,306 | 1,372 | +73 | +5.6% | 104,500 |
| 2018/11/07 | 1,311 | 1,312 | 1,278 | 1,299 | -30 | -2.3% | 119,600 |
| 2018/11/06 | 1,314 | 1,340 | 1,283 | 1,329 | +75 | +6% | 208,700 |
| 2018/11/05 | 1,236 | 1,265 | 1,231 | 1,254 | +26 | +2.1% | 44,200 |
| 2018/11/02 | 1,194 | 1,233 | 1,194 | 1,228 | +31 | +2.6% | 66,500 |
| 2018/11/01 | 1,212 | 1,219 | 1,186 | 1,197 | -12 | -1% | 47,000 |
| 2018/10/31 | 1,202 | 1,210 | 1,172 | 1,209 | +39 | +3.3% | 86,900 |
| 2018/10/30 | 1,110 | 1,176 | 1,110 | 1,170 | +14 | +1.2% | 91,800 |
| 2018/10/29 | 1,230 | 1,241 | 1,153 | 1,156 | -74 | -6% | 131,300 |
| 2018/10/26 | 1,306 | 1,325 | 1,230 | 1,230 | -69 | -5.3% | 114,400 |
| 2018/10/25 | 1,341 | 1,341 | 1,298 | 1,299 | -92 | -6.6% | 126,100 |
| 2018/10/24 | 1,410 | 1,428 | 1,362 | 1,391 | -16 | -1.1% | 67,200 |
| 2018/10/23 | 1,459 | 1,463 | 1,405 | 1,407 | -58 | -4% | 54,700 |
| 2018/10/22 | 1,461 | 1,473 | 1,442 | 1,465 | +3 | +0.2% | 29,500 |
| 2018/10/19 | 1,455 | 1,470 | 1,432 | 1,462 | -11 | -0.7% | 28,600 |
| 2018/10/18 | 1,471 | 1,502 | 1,463 | 1,473 | -8 | -0.5% | 38,500 |
| 2018/10/17 | 1,456 | 1,483 | 1,449 | 1,481 | +41 | +2.8% | 64,900 |
| 2018/10/16 | 1,413 | 1,456 | 1,413 | 1,440 | +7 | +0.5% | 44,900 |
| 2018/10/15 | 1,433 | 1,444 | 1,412 | 1,433 | +3 | +0.2% | 46,700 |
| 2018/10/12 | 1,430 | 1,447 | 1,401 | 1,430 | -30 | -2.1% | 106,800 |
| 2018/10/11 | 1,480 | 1,493 | 1,446 | 1,460 | -68 | -4.5% | 94,400 |
| 2018/10/10 | 1,526 | 1,550 | 1,500 | 1,528 | +4 | +0.3% | 68,900 |
| 2018/10/09 | 1,517 | 1,546 | 1,474 | 1,524 | +24 | +1.6% | 82,200 |
| 2018/10/05 | 1,476 | 1,514 | 1,451 | 1,500 | +27 | +1.8% | 83,500 |
| 2018/10/04 | 1,464 | 1,493 | 1,435 | 1,473 | -5 | -0.3% | 60,600 |
| 2018/10/03 | 1,535 | 1,547 | 1,474 | 1,478 | -77 | -5% | 109,800 |
| 2018/10/02 | 1,569 | 1,574 | 1,530 | 1,555 | +37 | +2.4% | 208,400 |
| 2018/10/01 | 1,519 | 1,556 | 1,518 | 1,518 | -16 | -1% | 71,400 |
1451～
1500
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたＣＡＲ－Ｔ細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
| 日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
| ＶＩＳ | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
| クリングル | 84,500円 | +240.0% | - | 0.00% | - | 2.75倍 |
|
細胞の増殖、保護、修復などの機能があるＨＧＦタンパク質を用いて、難治性疾患治療薬を開発 |
市場注目の銘柄
チャート関連のコラム
